INO Inovio Pharmaceuticals, Inc.

NASDAQ
$1.63

Inovio Pharmaceuticals, Inc. (INO) is expected to report earnings on February 9, 2027, after the market close. The consensus earnings estimate is a loss of $0.15 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +19.0% since its last earnings release on November 10, 2026.

Inovio Pharmaceuticals Missed Consensus Estimates
Tuesday, November 10, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 9
Tuesday · 4:05 PM ET
Earnings Whisper
-
vs ($0.15)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.45

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.